2005 - Memantine OCD Trial - UCLA
3. Safety and Efficacy of Namenda® (Memantine HCl) in the Treatment of Obsessive-Compulsive Disorder (Namenda Study).
Investigators: Alexander Bystritsky, M.D., Sanjaya Saxena, M.D., and Jamie Feusner, M.D.
This is a 12-week study for people with Obsessive Compulsive Disorder, either taking an SSRI (Prozac, Paxil, Celexa, or Zoloft) or on no medication at all. The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of Namenda® in the treatment of adults with OCD. The secondary purpose of this study is to evaluate whether adults treated with Namenda® have an overall increase in quality of life ratings.
Namenda® is FDA approved for the treatment of Alzheimer Disease, anecdotal evidence suggests Namenda® could be effective for the treatment of OCD. If you agree to this study you would be asked to come in every other week for about 8 weeks and then for a final visit one month later. Participants will be closely monitored for side effects and tolerance of the medication by their study doctor. You will receive $15 at each visit to reimburse you for transportation, parking, or other expenses related to your participation in this study. If you withdraw from the study early, you will be reimbursed for the portion of the study that you completed.
For more information, please call
(310) 206-5133
mentalhealth.ucla.edu |
